[Advances in perioperative systemic therapy for hepatocellular carcinoma].

The low surgical resection rate and high postoperative recurrence rate of hepatocellular carcinoma(HCC) are urgent clinical problems to be solved. Therefore, it is important to develop effective perioperative treatment. In recent years, a growing number of studies have shown that systemic therapy is expected to break through the limitations of traditional local treatment and play an important role in preoperative treatment. For example, some novel targeted agents and immunocheckpoint inhibitors have shown excellent potential as neoadjuvant treatment for HCC. Meanwhile, researchers have explored the application of systemic therapy as adjuvant therapy, but due to different criteria for patient selection, no consensus is reached on its efficacy. By far, there is no standard procedure for the application of systemic therapy in HCC perioperative period, little is known about the efficacy and safety of targeted drugs and immunotherapy. This article discusses the feasibility of systemic therapy as neoadjuvant and adjuvant treatment of HCC, as well as its adverse events, with an aim to provide new horizons of HCC systemic therapy in the perioperative period.肝癌手术切除率偏低和术后复发率较高是当前临床亟需解决的难题，寻求有效的围手术期治疗方案至关重要。越来越多的研究结果表明，系统治疗有望打破传统局部治疗的局限性，在肝癌术前治疗中发挥重要作用。如一些新型靶向药物及免疫检查点抑制剂，已在肝癌新辅助治疗中展现出良好的应用前景。同时，有学者探讨了系统治疗方案在肝癌术后的应用，但由于选择患者的标准不同，其有效性仍未达成共识。目前，系统治疗在肝癌围手术期的应用尚未形成统一的标准化流程，对于靶向药物及免疫疗法的有效性和安全性知之甚少。本文就系统治疗在肝癌术前与术后的可行性，以及围手术期需要关注的不良反应等方面进行探讨，以期为肝癌围手术期的系统治疗提供新思路。.